All In Biotech

Free tool

FAERS Monitor: Firdapse

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 208078 or its brand name (Firdapse, Amifampridine Phosphate). Reports on generic versions are filed under their own applications.

Reports

2,964

Serious

1,591

54% of reports

Hospitalization

806

Death reported

216

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • asthenia379
  • drug ineffective357
  • paraesthesia347
  • paraesthesia oral281
  • fall258
  • condition aggravated223
  • fatigue217
  • nausea210
  • muscular weakness204
  • headache191
  • diarrhoea177
  • dizziness175
  • dyspnoea168
  • off label use164
  • product dose omission issue164

Reports by year received

View as table
YearReports
20111
20176
20186
2019379
2020253
2021273
2022171
2023368
2024289
2025537
2026681

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,195 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
paraesthesia oralSignal281141.0126.038,179
paraesthesiaSignal34715.714.24,781
muscular weaknessSignal20412.811.22,207
astheniaSignal3797.26.52,036
fallSignal2585.54.9961
condition aggravatedSignal2235.24.6764
product dose omission issueSignal1644.03.4365
dizzinessSignal1752.52.2158
headacheSignal1912.21.9122
dyspnoeaSignal1682.11.899
fatigue2172.01.7108
diarrhoea1771.91.783
drug ineffective3571.91.7168
nausea2101.91.789
off label use1641.31.114

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.